2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Assays, Imaging, Molecular Testing, Omics Technologies, Cell Expansion, Emerging Technologies, Gene Editing, Treatment Considerations, Biological Therapies, Natural Killer (NK) Cell Therapies, Transplantation, Chimeric Antigen Receptor, (CAR)-T Cell Therapies, Immunotherapy, Artificial Intelligence (AI), Biological Processes, Genomics, Immune Mechanism, Metabolism, Molecular Biology, Diseases, Immunology, GVHD, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Plasma Cell Disorders, Myeloid Malignancies, Acute Myeloid Malignancies, Non-Hodgkin Lymphoma, B Cell Lymphoma, Research, Fundamental Science, AML, Translational Research, Study Population, Human, Animal Model
PAPER

5906 Cleavage enabled antigen reporter (CleavER): A Platform for high-throughput discovery of immunogenic T-cell epitopes.

Laura Teresa Morton, PhD, Laurence King2, Supreet Bola Kaur3, Maciej Szukszto4, Charlotte Boulton5, felix O'Farrell6, Hugh O'brein, PhD7, Sergio Quezada, PhD8, Marc R. Mansour, MD, PhD, FRCPath, MRCP9
1 University college London, London, United Kingdom
2 University college London, London, United Kingdom
3 University college London, London, United Kingdom
4 University college London, London, United Kingdom
5 University college London, London, United Kingdom
6 University college London, London, United Kingdom
7 Achilles Therapeutics, London, United Kingdom
8 University college London, London, United Kingdom
9 University college London, London, United Kingdom

T-cell receptor (TCR) based cellular-therapies are emerging as a promising treatment option against haematological and solid malignancies. These therapies rely upon TCR recognition of immunogenic epitopes presented in HLA-molecules on the surface of tumour cells, resulting in T-cell release of granzyme B and activation of pro-apoptotic pathways leading to tumour cell death. Therapeutic success is dependent on the computational prediction of immunogenic tumour antigens and currently only 2-3% of predicted antigens elicit a functional T-cell response. Identification of  immunogenic T-cell epitopes remains a challenge and is laborious due to the scale of the immunopeptidome landscape, highlighting the need for standardized, scalable platforms to accelerate therapeutic target discovery.

Here, we designed a novel Cleavage enabled Reporter (CleavER) to identify immunogenic T-cell epitopes in a high-throughput approach. CleavER links a protein-degradation tag mFKBP12, via a granzyme-B cleavage sequence to a fluorescent reporter protein and dTAG-13 treatment permits degradation of the CleavER reporter. Upon T-cell recognition of CleavER cells, granzyme-B cleaves the fluorescent reporter protein from the mFKBP12 tag and treatment with dTAG-13 results in recognised CleavER cells remaining reporter protein positive. For antigen screening, we lentivirally expressed antigenic DNA libraries, in mono-allelic CleavER cells, including positive controls derived from well characterised T-cell responses against CMV:NLV and NYESO:SLL epitopes restricted to HLA-A2. To determine if CleavER would function as an antigenic reporter, co-cultures with antigen-specific T-cells were conducted.

We demonstrated after co-culture with CMV-specific T-cells, mono-allelic HLA-A2+ CleavER cells expressing CMV:NLV remained reporter protein positive following treatment with dTAG-13. CleavER signal was dependent on both the frequency of Ag-specific T-cells and antigen bearing cells and CleavER sensitivity was shown to detect antigen as low as 1%. Furthermore, next generation sequencing revealed CMV:NLV was the only epitope enriched in reporter protein positive cells compared to reporter protein negative CleavER cells expressing an antigen library encoding 20,000 neoantigens, identifying CMV:NLV as an immunogenic T-cell epitope. Finally, CleavER signal improved 4-fold after knocking out SerpinB9, a granzyme B inhibitor, demonstrating the dependence on CleavER activity on Granzyme B cleavage.

In conclusion, CleavER is a scalable, high throughput platform which enables identification of specific functional immunogenic T-cell epitopes from complex antigen libraries. This approach has the potential to accelerate the identification of therapeutic epitopes for TCR-based cellular therapies.

Laura Teresa Morton, PhD: No relevant conflicts of interest to declare.